Status:
COMPLETED
GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Patients with Type 2 Diabetes.
Lead Sponsor:
University of Campania Luigi Vanvitelli
Conditions:
Diabetes Mellitus, Type 2
Myocardial Infarction
Eligibility:
All Genders
18-75 years
Brief Summary
Management of type 2 diabetes mellitus (T2DM) has evolved from a glucocentric to a cardiometabolic approach. Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-...
Detailed Description
Management of type 2 diabetes mellitus (T2DM) has evolved from a glucocentric to a cardiometabolic approach. Consequently, choosing anti-hyperglycemic therapies with proven cardiovascular and renal be...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Consecutive T2DM patients, treated with GLP-1 RA or SGLT-2i, with AMI;
- both STEMI and NSTEMI patients referred for PCI;
- Exclusion criteria:
- heart failure and valvular defects;
- inflammatory chronic diseases;
- neoplastic diseases.
Exclusion
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2024
Estimated Enrollment :
257 Patients enrolled
Trial Details
Trial ID
NCT06017544
Start Date
January 1 2017
End Date
December 1 2024
Last Update
January 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celestino Sardu
Naples, Naples, Italy, 80138